UN cautions virus plasma treatment still experimental
WHO considers plasma therapy to be experimental and that it should continue to be evaluated.
Trump announces plasma treatment authorized for COVID-19
FDA scientists says plasma should not be considered a new standard of care for the treatment of patients with COVID-19.
ProMetic Life Sciences signs Winnipeg plant to process plasma
Emergent BioSolutions facility will process up to 250,000 litres of plasma annually.
ProMetic and SSB expand their plasma purification efforts
Expanded strategic deal includes equipment and co-commercialization.
ProMetic extends its reach in Asian markets with $21M deal
R&D project will expand Shenzhen Hepalink’s product line and diversification efforts.
ProMetic turns loss around in Q2
Doubles revenues, records a profit of $800,000
ProMetic, NantPharma form US biopharmaceutical company
NantPro will manufacture plasma-derived product for US market.
ProMetic gets $4.6M Octapharma order
PrioClear prion capture resin is used in plasma product production.
ProMetic and Hematech close $10M orphan drug deal
ProMetic Life Sciences Inc. in Laval, Que. has signed a $10-million strategic manufacturing and licence deal with a drug manufacturer in Taiwan to co-develop and commercialize a pharma product that targets a rare medical condition (orphan).